Purpose: Persistent pulmonary hypertension of the newborn (PPHN) is a potentially fatal disease. Inhaled iloprost, a stable analogue of prostacyclin, has recently been used as a therapeutic option. However, there are no clinical guidelines on the use of ilo prost, specifically for neonates. This study aimed to suggest the use of inhaled iloprost as a rescue therapy for PPHN based on our experience. Methods: The efficacy and adverse events of inhaled iloprost were evaluated pro spectively in nine fullterm neonates with PPHN. We monitored the following para meters: fraction of inspired oxygen (FiO 2 ), respiratory severity score (RSS), heart rate, and mean blood pressure. Results: The inhalation dose was 1 to 2 μg/kg initially, and 4 to 8 inhalations per day were applied over 2 to 8 days, except in the case of one neonate who died 2 days after birth. Echocardiographic findings, changes in FiO 2 , and RSS improved within the next 7 days in eight of the nine patients. Severe side effects on heart rate and blood pressure were not observed. Conclusion: Our experience suggests that inhaled iloprost can be used as a firstline treatment in newborn infants with PPHN when inhaled nitric oxide is not available. To the best of our knowledge, this report is the first prospective case series on the use of inhaled iloprost in PPHN.
INTRODUCTION
Persistent pulmonary hypertension of the newborn (PPHN) is a serious disorder that results from the failure of normal pulmonary vascular adaptation at or soon after birth, and its estimated incidence is approximately 2 per 1,000 live births 1) . Highfrequency ventilation, inhaled nitric oxide (iNO), and extracorporeal membrane oxygenation have improved outcomes. However, several facilities do not offer these therapies due to their high costs and insufficient infrastructure. Furthermore, the Food and Drug Administration (FDA) recently issued a warning regarding the use of sildenafil to treat pediatric pulmonary arterial hypertension after an unexpectedly high mortality rate was observed among children receiving the drug in high doses in a clinical trial 2) . Therefore, there is a significant need for new, alternative modalities to treat PPHN in neonates. Inhaled iloprost, a stable analogue of prostacyclin (PGI2), may be an adjunctive or rescue therapy option for infants with PPHN. However, case reports regarding its use as an emergency treatment for PPHN are still preliminary 37) .
In our center, we used iloprost and other medications to treat PPHN at a time when iNO was not available because medically approved NO gas (iNOmax) was not yet introduced in Korea, and for other NO gases, we were not convinced of their safety.
This report aimed to describe the effects of rescue attempts with inhaled iloprost on mechanically ventilated PPHN patients. Addi tionally, we have evaluated the therapeutic efficacy and safety of inhaled iloprost for the treatment of PPHN when inhaled iNO was not available.
MATERIALS AND METHODS

Perinatal characteristics of the case series
We prospectively enrolled nine fullterm neonates (≥37 weeks' gestation) with idiopathic or associated pulmonary arterial hypertension in this iloprost inhalation trial at the neonatal in tensive care unit of Hanyang University Medical Center between March 2009 and August 2013. Neonates were excluded if they met one of the following criteria: (1) oxygenation index >25, assessed using an arterial blood gas analyzer; (2) need for immediate cardiopulmonary resuscitation; (3) presence of con genital heart disease; or (4) hemodynamic instability (mean arterial pressure <5th percentile for their age). The respiratory severity score (RSS) was calculated by multiplying the fraction of inspired oxygen (FiO2) by the mean airway pressure. 
Iloprost dosage and administration
Inhaled iloprost (20 μg/2 mL, Ventavis, Bayer, Leverkusen, Germany) was administered at an initial dosage of 1 to 2 μg/ kg by integrating a nebulizer into the ventilator system without dis connecting the mechanical ventilator. The initial dosage was calculated to achieve a previously reported theoretical alveolar deposition 8) . One ampoule of iloprost was diluted with 4 to 6mL of distilled water. We used the PARI BOY SX type 085 (Pari GmbH, Starnberg, Germany) nebulizer for highfrequency oscillation and the Servo Ultra Nebulizer (Maquet, Solna, Sweden) for the Servoi ventilator.
Outcomes
The efficacy of iloprost was compared before and 24, 48, 72 hours, and 1 week after the use of inhalation with echocardio graphic findings, RSS, and FiO2. Serial echocardiography was performed according to the patients' situation or onduty status of the medical staff. Bronchoconstriction, which was a known adverse effect of iloprost, was also observed by the medical staff.
Each single inhalation lasted over 10 minutes and was repeated every 3 to 4 hours, based on decreases in the postductal arterial saturation from the value immediately following the previous iloprost inhalation. The medication and ventilator settings were maintained unchanged during inhalation.
Statistical analysis
Statistical analysis was performed using the SPSS version 16.0 (SPSS, Chicago, IL, USA). All variables were expressed as the mean±standard deviation, and the Wilcoxon signedrank test was used to compare respiratory and hemodynamic changes before and after the start of iloprost. Differences were considered significant when Pvalue was <0.05.
RESULTS
The demographic and clinical characteristics of the patients are presented in Table 1 . All nine fullterm neonates were referred from primary care, and six were boys. The median gestational age and birth weight were 38 +4 weeks (37 +1 to 40 +2 ) and 3.42 kg (2.84 to 4.39), respectively. Three patients were born by spontaneous vaginal delivery, and six were delivered by cesarean section.
Severe respiratory failure caused by meconium aspiration syn drome, sepsis, asphyxia, and respiratory distress syndrome were associated with the pathogenesis of PPHN. Patient no. 8 was transferred after recurrence of PPHN due to aspiration pneumo nia noted at the age of 21 days.
Iloprost was inhaled at an initial dose of 1 to 2 μg/kg/day and subsequently administered every 3 to 6 hours for 2 to 8 days in survivors by connecting an ultrasonic nebulizer to the inspiratory limb of the ventilator circuit. Inotropic support with dopamine and dobutamine was started to maintain systemic blood pressure
at normal values for gestational ages in five patients 1) . Surfactant administration and oral sildenafil were combined with iloprost in five and eight patients, respectively. The dose of oral sildenafil for each patient ranged from 1.0 to 2.8 mg/kg/dose.
Fentanyl and midazolam sedation was administered in six patients who showed intolerance to mechanical ventilation (Table 1) . Table 2 evidence of side effects in eight of the nine patients. There were no significant changes in heart rate and mean blood pressure after iloprost inhalation ( Figure 2 ). Moreover, no adverse effects that could be attributed to iloprost were observed.
Details of the outcomes after iloprost inhalation therapy are shown in Table 3 . All patients were supported by highfrequency oscillation ventilation or pressurecontrolled ventilation. The mean duration of oxygen therapy was 8.4±3.0 days. Enteral feeding was started in infants who were at least 6 days old, and the number of days to full enteral feeding was 9.4±1.3 days, ranging from 8 to 11 days. Eight of the nine patients made a full recovery and were discharged from the hospital within 3 weeks, ranging from 10 to 18 days. However, one patient with severe hypoxic damage and multiorgan failure when he was referred showed a tension pneumothorax in both sides of the lungs and a large PDA.
He died due to a lack of response to treatment 2 days after his birth.
DISCUSSION
The main reason why inhaled iloprost is more preferred than iNO is its readily availability and comparable clinical effects, while iNO is cost prohibitive and requires special monitoring for side PPHN is a complex clinical syndrome with significant mor bidity and mortality 9) . iNO, inhaled iloprost, and phosphodieste rase inhibitors (sildenafil) are known treatment options that are used along with supportive care such as alkalinization and high frequency oscillatory ventilation in neonates with PPHN. iNO has a selective effect on the pulmonary vasculature through the guanosine 3' ,5'cyclic monophosphate and has become well established as the firstline therapy for PPHN 10, 11) . However, iNO therapy is still unavailable in many developing countries. Al though pulmonary hypertension in adults is commonly treated with PGI2 analogues (treprostinil, iloprost, or epoprostenol), endo thelin receptor antagonists (bosentan and ambrisentan), and pho sphodiesterase type 5 inhibitors (sildenafil) 12) , few reports have addressed the use of these treatments in neonates and preterm infants 3, 4, 1317) . The pharmacokinetics of oral sildenafil in neonates with decreased gastric motility remain uncertain. Moreover, the FDA issued a warning regarding the pediatricspecific side effects of sildenafil, including hypotension and hemoptysis 2) .
Therefore, there is an increasing interest in the potential benefit of inhaled iloprost in neonates. In 2014, Kahveci et al. 18) compared the effectiveness and safety of oral sildenafil and inhaled iloprost therapy for PPHN in a referral center located in a lowincome re gion of Turkey. Results showed that iloprost was considered to be more effective than sildenafil in the treatment of PPHN with regard to time to clinical response, ventilator/respiratory parameters, and combined drug admini stration 18) . However, it seems to be impossible to evaluate the isolated effects of both drugs in the clinical field due to ethical issues.
Iloprost is a PGI2 analogue, and PGI2 is a member of the prosta noid group of eicosanoids, which regulate homeostasis, smooth muscle function, and inflammation 19) . PGI2 is produced by endo thelial cells and influences several cardiovascular processes by increasing adenosine 3' ,5'cyclic monophosphate levels. This mechanism could explain the beneficial effect of iloprost on nonresponders to inhaled iNO and the additive effect of combin ing both agents 11) . of aerosolized application into a mechanical ventilator, and uncertainties about optimal dosage and the time to achieve a significant effect in neonates 5, 7) . Han et al. 20) reported the thera peutic effect of inhaled iloprost in newborn infants with severe PPHN refractory to iNO but enrolled only a small number of cases retrospectively. Although clinical data are few, inhaled iloprost, single or combined, has been useful and effective as a rescue or additional treatment for improving oxygenation in cases of acute pulmonary hypertension in children, bronchopulmonary dysplasia, postoperative pulmonary hypertensive crisis in children with congenital heart disease, and pulmonary hyper tension in preterm infants in addition to PPHN 4, 8, 11, 15, 16, 21) .
Our study could provide useful guidelines on the clinical trials of inhaled iloprost in terms of available dosage and the timing of inhaled iloprost for neonates. Moreover, iloprost might be an alternative drug treatment that improves oxygenation in the absence of iNO. Adverse effects of bronchoconstriction or unstable hemodynamics such as hypotension have sometimes been observed during iloprost nebulization in older children 13) .
However, compared to that with the systemic application of PGI2 22) , the rate of adverse effects with iloprost seems to be ne gligible. In our study, adverse effects were not observed.
This study has several limitations, that is, the total number of cases may be considered insufficient and they were all from a single center. Given that a control group is not set up, we cannot exclude the positive effects from other applied drugs such as a surfactant and sildenafil.
In conclusion, our clinical experience supports that nebulized iloprost, with or without concomitant oral sildenafil, is a safe and promising therapy for PPHN, specifically when inhaled NO is unavailable. However, larger controlled studies are required to confirm the clinical usefulness of inhaled iloprost and to define its safety and efficacy alone or in combination with other vasodilator drugs.
ARTICLE INFORMATION Ethical statement
The study was approved by Institutional Review Board (IRB) of Hanyang University Medical Center (IRB No. 201505027009).
Written informed consent was obtained from the parents of every neonate before their enrollment in the study.
Conflicts of interest
No potential conflict of interest relevant to this article was reported.
Author contributions
Conception or design: H.K.P.
Acquisition, analysis, or interpretation of data: H.J.L., N.S.K.
Drafting the work or revising: S.H.K.
Final approval of the manuscript: S.H.K., H.K.P.
ORCID
Seung Hyun Kim https://orcid.org/0000000257405688
HyunKyung Park https://orcid.org/0000000159569208
